Poster Tour 1: Social Science
Tracks
Track 1
Track 2
Wednesday, September 11, 2019 |
3:30 PM - 4:00 PM |
Level 8 |
Speaker
Mr Darcy Bowman
Associate Director
Gilead Sciences Europe
#112 BEYOND CLINICAL OUTCOMES: IMPACT AND WIDER SOCIAL AND HEALTHCARE SYSTEM IMPLICATIONS OF HEPATITIS C VIRUS (HCV) TREATMENT AND CURE
3:30 PM - 3:35 PMBiography
Professor Torrens has extensive experience in the addiction field and current serves as the Head of the Addiction Programme at the Institute of Neuropsychiatry and Addictions-Parc de Salut Mar, Barcelona. Additionally, she is also a Member of the Clinical Commission of the National Plan on Drugs, Spanish Ministry of Health.
Dr Susan Chong
Lecturer/Research Fellow
La Trobe University
#113 HEPATITIS C TREATMENT: PEER INSIGHTS TO UNDERSTANDING ENABLERS AND IMPEDIMENTS TO DAA UPTAKE AMONG PEOPLE WHO INJECT DRUGS
3:35 PM - 3:40 PMBiography
Susan is a Research Fellow at the Australian Research Centre in Sex, Health and Society at La Trobe University in Melbourne, Australia. Her research focus is on HIV and hepatitis C among vulnerable and marginalised communities in Australia and the Asia Pacific region. She is also a public health lecturer.
Dr Marie Jauffret-Roustide
Research Fellow
INSERM
#116 HCV CRISIS AMONG RUSSIAN-SPEAKING INJECTING DRUG USERS IN FRANCE: THE URGENT NEED TO IMPROVE ACCESS TO CARE AND SOCIAL INTEGRATION
3:40 PM - 3:45 PMBiography
Marie Jauffret-Roustide is a Sociologist, Research Fellow at Inserm in France. Her research focuses mainly on harm reduction policies including HCV, migration, and gender issues in drug policies as well as patient groups' involvement. She has coordinated several evaluative intervention studies among vulnerable populations, using a community-based research approach.
Mr George Kalamitsis
Chair
Hellenic Liver Patient Association "prometheus"
#117 FACTORS ASSOCIATED WITH LOW RATES OF ENGAGEMENT IN OPIOID SUBSTITUTION TREATMENT AMONG PEOPLE WHO USE DRUGS IN ATHENS
3:45 PM - 3:50 PMBiography
George Kalamitsis is Chair of Hellenic Liver Patients Association "Prometheus", since 2012. He is also a member of the Committee monitoring the Greek Action Plan for hepatitis C, as well as President of the Committee Protecting the Rights of Recipients of Health Services under the Greek Ministry of Health
Mr. Adam Palayew
Student
McGill University Department of Epidemiology
#120 THE IMPLEMENTATION OF HARM REDUCTION AND HEPATITIS C SERVICES FOR PEOPLE WHO INJECT DRUGS IN EUROPE: RESULTS FROM THE 2018 HEP-CORE SURVEY
3:50 PM - 3:55 PMBiography
Adam Palayew is a young researcher with training from McGill University in Epidemiology and Biostatistics. He has a wide range of interest from cutting-edge statistical methods to patient advocacy and reducing the gap between policy and practice. His main research focuses on social determinants of health around HIV/HCV co-infection.
Dr. Bruce Schackman
Professor
Weill Cornell Medicine
#121 COST OF HEPATITIS C CARE FACILITATION FOR HIV/HEPATITIS C CO-INFECTED PEOPLE WHO USE SUBSTANCES
3:55 PM - 4:00 PMBiography
Dr. Schackman is a Professor of Healthcare Policy & Research at Weill Cornell Medicine and Director of the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH). He conducts economic evaluations alongside clinical trials and cohort studies, cost-effectiveness simulation modeling, and implementation science studies.
Chair
Lise Lafferty
Research Fellow
UNSW Sydney